INTRODUCTION: Levetiracetam (LEV) is used in the setting of acute brain injury for seizure treatment or prophylaxis but its safety and efficacy in this setting is unknown. METHOD: We retrospectively analyzed the patterns of use and safety/efficacy of LEV in 379 patients treated in the neuroscience intensive care unit (NSICU). We extracted from the charts clinical data including diagnosis, AED therapy before and during stay in the NSICU, complications of treatment, length of stay, and clinical outcomes (improvement, Glasgow Coma Scale, and death). We analyzed the data using binary and ordered (multi-category) logistic regression. RESULTS: Overall, our findings are that phenytoin used prior to the NSICU admission was frequently replaced with LEV monotherapy (P < 0.001). Patients treated with LEV monotherapy when compared to other AEDs had lower complication rates and shorter NSICU stays. Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0.014). DISCUSSION: The results of this study suggest that LEV is a frequently used AED in the setting of acute brain injury and that it may be a desirable alternative to phenytoin. Prospective studies evaluating the long-term safety, efficacy and outcomes of LEV in this setting are indicated.
INTRODUCTION: Levetiracetam (LEV) is used in the setting of acute brain injury for seizure treatment or prophylaxis but its safety and efficacy in this setting is unknown. METHOD: We retrospectively analyzed the patterns of use and safety/efficacy of LEV in 379 patients treated in the neuroscience intensive care unit (NSICU). We extracted from the charts clinical data including diagnosis, AED therapy before and during stay in the NSICU, complications of treatment, length of stay, and clinical outcomes (improvement, Glasgow Coma Scale, and death). We analyzed the data using binary and ordered (multi-category) logistic regression. RESULTS: Overall, our findings are that phenytoin used prior to the NSICU admission was frequently replaced with LEV monotherapy (P < 0.001). Patients treated with LEV monotherapy when compared to other AEDs had lower complication rates and shorter NSICU stays. Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0.014). DISCUSSION: The results of this study suggest that LEV is a frequently used AED in the setting of acute brain injury and that it may be a desirable alternative to phenytoin. Prospective studies evaluating the long-term safety, efficacy and outcomes of LEV in this setting are indicated.
Authors: Andrew M Naidech; Kurt T Kreiter; Nazli Janjua; Noeleen Ostapkovich; Augusto Parra; Christopher Commichau; E Sander Connolly; Stephan A Mayer; Brian-Fred M Fitzsimmons Journal: Stroke Date: 2005-01-20 Impact factor: 7.914
Authors: K A Schulman; J A Berlin; W Harless; J F Kerner; S Sistrunk; B J Gersh; R Dubé; C K Taleghani; J E Burke; S Williams; J M Eisenberg; J J Escarce Journal: N Engl J Med Date: 1999-02-25 Impact factor: 91.245
Authors: J R White; T S Walczak; I E Leppik; J Rarick; T Tran; T E Beniak; D J Matchinsky; R J Gumnit Journal: Neurology Date: 2003-11-11 Impact factor: 9.910
Authors: Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy Journal: J Child Neurol Date: 2011-01-13 Impact factor: 1.987
Authors: Patrick M Kochanek; Travis C Jackson; Nikki Miller Ferguson; Shaun W Carlson; Dennis W Simon; Erik C Brockman; Jing Ji; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Anthony E Kline; Philip E Empey; Robert S B Clark; Edwin K Jackson; C Edward Dixon Journal: Semin Neurol Date: 2015-02-25 Impact factor: 3.420
Authors: Kristen E Jones; Ava M Puccio; Kathy J Harshman; Bonnie Falcione; Neal Benedict; Brian T Jankowitz; Martina Stippler; Michael Fischer; Erin K Sauber-Schatz; Anthony Fabio; Joseph M Darby; David O Okonkwo Journal: Neurosurg Focus Date: 2008-10 Impact factor: 4.047